Search Results - "Gaetano, J. N."

Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease by Christensen, B., Micic, D., Gibson, P. R., Yarur, A., Bellaguarda, E., Corsello, P., Gaetano, J. N., Kinnucan, J., Rao, V. L., Reddy, S., Singh, S., Pekow, J., Rubin, D. T.

“…Summary Background Blocking of lymphocyte trafficking to bile ducts is a potential mechanism to alter the disease course of patients with primary sclerosing…”
Get full text

Benefit-risk assessment of new and emerging treatments for hepatitis C: focus on simeprevir and sofosbuvir by Gaetano, John N

“…Greater understanding of the hepatitis C virus (HCV) genome and life cycle of the HCV virion allows for new targets for therapy that directly act on the viral…”
Get full text